Infection and Inflammation as Risk Factors for Thrombosis and Atherosclerosis

被引:118
作者
Levi, Marcel [1 ]
van der Poll, Tom [1 ,2 ,3 ]
Schultz, Marcus [4 ,5 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Med, NL-1105 AZ Amsterdam, Netherlands
[2] Ctr Infect & Immun Amsterdam CINIMA, Amsterdam, Netherlands
[3] Expt Med Lab, Amsterdam, Netherlands
[4] Lab Expt Intens Care & Anesthesiol, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands
关键词
infection; inflammation; thrombosis; atherosclerosis; coagulation; endothelium; cytokines; DISSEMINATED INTRAVASCULAR COAGULATION; TISSUE FACTOR EXPRESSION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HEMOLYTIC-UREMIC SYNDROME; NECROSIS-FACTOR-ALPHA; C-REACTIVE PROTEIN; PLASMINOGEN-ACTIVATOR-INHIBITOR-1; GENE; EXPERIMENTAL ENDOTOXEMIA; ANTICOAGULANT PATHWAYS; POLYARTERITIS-NODOSA;
D O I
10.1055/s-0032-1305782
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Severe infection and inflammation almost invariably lead to hemostatic abnormalities, ranging from insignificant laboratory changes to gross activation of coagulation that may result in localized thrombotic complications or systemic intravascular fibrin deposition. Systemic inflammation results in activation of coagulation, due to tissue factor-mediated thrombin generation, downregulation of physiological anticoagulant mechanisms, and inhibition of fibrinolysis. Proinflammatory cytokines, immune cells, and the endothelium play a central role in the differential effects on the coagulation and fibrinolysis pathways. Vice-versa, activation of the coagulation system may importantly affect inflammatory responses by direct and indirect mechanisms. Similar mechanisms appear to play a role in the development of atherosclerosis and related arterial thrombosis. Apart from the general coagulation response to inflammation associated with severe infection, specific infections may cause distinct features, such as hemorrhagic fever or thrombotic microangiopathy.
引用
收藏
页码:506 / 514
页数:9
相关论文
共 128 条
[1]
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[2]
Ackerman B, 1997, INFLAMMATORY DIS HIS, P170
[3]
Toll-like receptors in the induction of the innate immune response [J].
Aderem, A ;
Ulevitch, RJ .
NATURE, 2000, 406 (6797) :782-787
[4]
Vascular bed-specific hemostasis: Role of endothelium in pathogenesis [J].
Aird, WC .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S28-S34
[5]
Anas AA, 2010, NETH J MED, V68, P147
[6]
EVALUATION OF A PORTABLE PROTHROMBIN TIME MONITOR FOR HOME-USE BY PATIENTS WHO REQUIRE LONG-TERM ORAL ANTICOAGULANT-THERAPY [J].
ANDERSON, DR ;
HARRISON, L ;
HIRSH, J .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (12) :1441-1447
[7]
VARICELLA HEPATITIS - A FATAL CASE IN A PREVIOUSLY HEALTHY, IMMUNOCOMPETENT ADULT [J].
ANDERSON, DR ;
SCHWARTZ, J ;
HUNTER, NJ ;
COTTRILL, C ;
BISACCIA, E ;
KLAINER, AS .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (18) :2101-2106
[8]
Hemolytic uremic syndrome as a presenting form of HIV infection [J].
Badesha, PS ;
Saklayen, MG .
NEPHRON, 1996, 72 (03) :472-475
[9]
Atherosclerosis: An infectious disease? [J].
Benitez, RM .
HOSPITAL PRACTICE, 1999, 34 (09) :79-+
[10]
Benitez RM., 1999, HOSP PRACT, V34, P85